Our precision-focused approach to cancer research combines molecular and clinical expertise with insights from causal human biology to help guide scientific discovery. Learn more about our approach to cancer research: bit.ly/47ZQ0zr #ESMO26 #OneBMS

MTAP deletion is a genomic alteration found across multiple tumor types. Explore the biology and evolving unmet need in this patient population: bit.ly/4dXxXND #ESMO26

Today at #ESMO26, we presented late-breaking results from a Phase 3 study in patients with EGFR-mutant #NSCLC. View the presentation: bit.ly/4i1UP0O Learn more about the role of bispecific antibody-drug conjugates: bit.ly/4iByozF

Join us tomorrow at #ESMO26 as Dr. Byoung Chul Cho presents efficacy and safety results from LBA76 Phase 2 ROSETTA Lung-107 trial. Explore our research: bit.ly/4zI4GyF #NSCLC #LungCancer #BioNTech_Group

Join us at #ESMO26 as we explore emerging therapeutic strategies in prostate and bladder cancer—from androgen receptor (AR)-directed innovations and radiopharmaceuticals to novel antibody-drug conjugate (ADC) approaches helping shape the future of care.

Tomorrow at #ESMO26, Dr. @sara_lonardi1 will present the final overall survival results from the Phase 3 CheckMate 8HW study in MSI-H/dMMR metastatic colorectal cancer (#CRC). Explore our research: bit.ly/4kbFSup

Join us tomorrow at #ESMO26 for a rapid oral presentation analyzing brain metastases subgroups from two Phase 2 studies in small-cell lung cancer (#SCLC) and triple-negative breast cancer (#TNBC). Explore our research: bit.ly/3W43Uh0 #BioNTech_Group

On October 23 at #ESMO26, we’ll present late-breaking results from a randomized Phase 3 study in patients with previously treated or unresectable locally advanced or metastatic HR+/HER2- breast cancer. Explore our research: bit.ly/4ie6okw

Lung cancer care is evolving fast. Join us at #ESMO26 as we explore how to advance the non-small cell lung cancer (#NSCLC) treatment landscape — from today’s standards of care to tomorrow’s emerging modalities—to shape what comes next for patients.

Join us at #ECNP2026 as Dr. Leslie Citrome, Dr. Robert Perneczky and Dr. Silvana Galderisi explore the role of the cholinergic system in schizophrenia, bipolar disorder, and Alzheimer’s disease and discuss the therapeutic potential of muscarinic modulation in psychiatry.